Press coverage about Aimmune Therapeutics (NASDAQ:AIMT) has trended positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Aimmune Therapeutics earned a media sentiment score of 0.28 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 46.2509940624797 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the media stories that may have impacted Accern’s analysis:
Several research analysts recently issued reports on AIMT shares. Credit Suisse Group raised their target price on Aimmune Therapeutics from $36.00 to $45.00 and gave the stock an “outperform” rating in a research report on Monday, October 23rd. Piper Jaffray Companies set a $38.00 target price on Aimmune Therapeutics and gave the stock a “buy” rating in a research report on Saturday, October 21st. Zacks Investment Research raised Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, August 29th. Wedbush reaffirmed an “outperform” rating and set a $70.00 target price (up from $42.00) on shares of Aimmune Therapeutics in a research report on Monday, October 23rd. Finally, BidaskClub lowered Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $49.40.
Aimmune Therapeutics (NASDAQ:AIMT) traded up $0.16 during mid-day trading on Wednesday, hitting $35.74. The stock had a trading volume of 192,336 shares, compared to its average volume of 357,994. Aimmune Therapeutics has a 1 year low of $15.97 and a 1 year high of $37.50.
Aimmune Therapeutics (NASDAQ:AIMT) last posted its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.63) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.72) by $0.09. research analysts predict that Aimmune Therapeutics will post -2.63 earnings per share for the current year.
In related news, CEO Stephen George Dilly sold 1,154 shares of the business’s stock in a transaction dated Monday, October 16th. The stock was sold at an average price of $26.24, for a total value of $30,280.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Mary M. Rozenman sold 30,000 shares of the business’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $22.50, for a total value of $675,000.00. Following the completion of the sale, the insider now directly owns 30,129 shares of the company’s stock, valued at $677,902.50. The disclosure for this sale can be found here. Over the last three months, insiders sold 317,720 shares of company stock valued at $8,400,244. Corporate insiders own 17.59% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This news story was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another site, it was illegally stolen and reposted in violation of United States and international copyright laws. The legal version of this news story can be read at https://www.dispatchtribunal.com/2017/11/22/positive-news-coverage-somewhat-unlikely-to-affect-aimmune-therapeutics-aimt-stock-price.html.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.